We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





AACC Launches COVID-19 Immunity Study at 2021 Annual Scientific Meeting and Clinical Lab Expo

By LabMedica International staff writers
Posted on 31 Aug 2021
The American Association for Clinical Chemistry (AACC; Washington, DC, USA) is launching the COVID-19 Immunity Study, which will examine immune responses to SARS-CoV-2 vaccination or prior infection in a diverse group of volunteers.

Despite continued efforts by the scientific community to understand all aspects of COVID-19, it is still not known how long the currently available SARS-CoV-2 vaccines can provide protection against the SARS-CoV-2 virus. More...
In order to gain further insights into this issue, AACC’s study will also further examine the utility of serologic tests as a means to measure lasting immunity.

AACC will collect blood samples for the planned study from attendees and exhibitors at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo to be held in Atlanta on September 28-30. All study participants must be 18 years of age and efforts will be made to ensure that the research cohort is as diverse as possible. This approach to sample collection is modeled after AACC’s Universal Sample Bank program, which used samples from attendees of the 2015 AACC Annual Scientific Meeting in support of important research related to troponin. People who are unable to attend the meeting in person can also contribute to the study by submitting answers to a 10-minute COVID-19 health questionnaire. In return for donating blood, the study participants will receive the results of their individual antibody profile tests after all the collected samples have been analyzed.

Related Links:
American Association for Clinical Chemistry


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining System
RAL DIFF-QUIK
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








ADLM

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.